Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the safety and describe the steady-state plasma
pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation)
following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension
patients.